Utah insurer to pay enrollees to buy prescriptions from Mexico

As healthcare prices and prescription drug costs continue to soar in the United States, one insurer in Utah is taking an innovative approach to reducing costs—by offering to pay its enrollees to fill prescription medications in Mexico, The Salt Lake Tribune reported.

PEHP, a Utah-based health plan that covers 160,000 public employees and family members, has rolled out a pharmacy tourism option to some of its enrollees, which will allow them to fly to San Diego, go to Tijuana, Mexico, and take a $500 cash payout to buy their medicines there. The option applies to some patients who need certain expensive drugs for multiple sclerosis (MS), cancer and autoimmune disorders, covering about a dozen drugs, the Tribune reported.

One drug under the policy that treats MS, Avonex, costs about $6,700 for a 28-day supply in the U.S., but only about $2,200 in Tijuana.

The option was rolled out as a result of new legislation that required insurance plans of state employees to offer savings rewards to patients who choose cheaper providers.

“Why wouldn’t we pay $300 to go to San Diego, drive across to Mexico and save the system tens of thousands of dollars?” state Rep. Norman Thurston, R-Provo, who sponsored the legislation calling for incentives, told the Tribune. “If it can be done safely, we should be all over that.”

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.